KLI
ANIP icon

Kelman-Lazarov Inc’s ANI Pharmaceuticals ANIP Stock Holding History

Kelman-Lazarov Inc’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed -$60 – 109
2016
Q4 		$60 Hold
1
– – ﹤0.01% 305
2016
Q3 		$67 Hold
1
– – ﹤0.01% 376
2016
Q2 		$57 Hold
1
– – ﹤0.01% 369
2016
Q1 		$0 Buy
+1
New +$34 ﹤0.01% 356

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Kelman-Lazarov Inc's ANIP Position: Q1 2017 in Review

Kelman-Lazarov Inc sold out of ANI Pharmaceuticals (ANIP) in Q1 2017, closing a stake of 1 share — an estimated $60 sold.

Kelman-Lazarov Inc first reported a position in ANIP in Q1 2016 and held it in 4 quarters. The position peaked at $67 in Q3 2016. 158 funds tracked by Wall St. Rank hold ANIP as of Q1 2017.

  • Kelman-Lazarov Inc reported no remaining ANI Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 1 ANI Pharmaceuticals share in Q1 2017, an estimated $60.
  • Kelman-Lazarov Inc first reported a position in ANI Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Kelman-Lazarov Inc's ANI Pharmaceuticals position peaked at $67 in Q3 2016.
  • 158 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2017.

Based on Kelman-Lazarov Inc's 13F filing for Q1 2017, filed 25 Apr 2017.